Literature DB >> 1895160

BCNU stability as a function of ethanol concentration and temperature.

P Tepe1, S J Hassenbusch, R Benoit, J H Anderson.   

Abstract

BCNU is increasingly used in low ethanol (ETOH) concentrations, 5% dextrose-water (D5W), or normal saline (NS) solutions, especially for intra-arterial and prolonged (e.g., 3 day) intravenous (IV) infusions. Little work, however, has been done to evaluate BCNU decomposition rates in concentrations, diluents, and temperatures similar to those employed clinically. This study examined BCNU solutions in ETOH, NS, and D5W to evaluate, conclusively, initial recovery and decomposition rates in these three diluents. Initial BCNU recovery rates were: 95.6 +/- 0.3% (100% D5W), 89.6 +/- 0.5% (15% ETOH), and 85.2 +/- 0.5% (NS) (P less than 0.001). Study of all solutions revealed no measurable BCNU decomposition over 24 hrs (0 degrees C) and no significant difference in decomposition rates between any of the diluents (19.5 degrees C). At 37 degrees C, the solutions showed different half-lives: 14.3 +/- 0.19 hrs (15% ETOH), 10.6 +/- 0.02 hrs (10% ETOH), 8.2 +/- 0.21 hrs (5% ETOH), 7.3 +/- 0.06 hrs (NS), and 6.8 +/- 0.07 hrs (D5W) (P less than 0.001). Decomposition rates between all three temperatures (19.5 degrees C, 37 degrees C, and 50 degrees C) were significantly different (P less than 0.01) for each diluent. Dissolving BCNU powder into either D5W or NS required only 5 min when hand-shaken at body temperature. This study of initial recovery and decomposition rates suggests that, although BCNU decomposition rates were significantly increased at body temperature (37 degrees C), it was quite low and essentially unaffected by different diluents at room temperature (i.e., 19.5 degrees C).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1895160     DOI: 10.1007/bf00146872

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  14 in total

1.  Degradation of carmustine in aqueous media.

Authors:  P A Laskar; J W Ayres
Journal:  J Pharm Sci       Date:  1977-08       Impact factor: 3.534

2.  Nitrosourea chemotherapy for primary malignant gliomas.

Authors:  V A Levin; C B Wilson
Journal:  Cancer Treat Rep       Date:  1976-06

3.  Colorimetric method for the determination of 1,3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  T L Loo; R L Dion
Journal:  J Pharm Sci       Date:  1965-05       Impact factor: 3.534

4.  Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962.

Authors:  V T De Vita; P P Carbone; A H Owens; G L Gold; M J Krant; J Edmonson
Journal:  Cancer Res       Date:  1965-12       Impact factor: 12.701

5.  Distribution of Bratton-Marshall-positive material in mice following intravenous injections of nitrosoureas.

Authors:  P Kari; W R McConnell; J M Finkel; D L Hill
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

6.  Neurological deficit after carotid infusion of cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for malignant glioma: an analysis of risk factors.

Authors:  J P Kapp; R A Sanford
Journal:  Neurosurgery       Date:  1986-11       Impact factor: 4.654

7.  BCNU solubility and toxicity in the treatment of malignant astrocytomas.

Authors:  P B Layton; H S Greenberg; P L Stetson; W D Ensminger; J W Gyves
Journal:  J Neurosurg       Date:  1984-06       Impact factor: 5.115

8.  Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.

Authors:  H S Greenberg; W D Ensminger; W F Chandler; P B Layton; L Junck; J Knake; A K Vine
Journal:  J Neurosurg       Date:  1984-09       Impact factor: 5.115

Review 9.  1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review.

Authors:  S K Carter; F M Schabel; L E Broder; T P Johnston
Journal:  Adv Cancer Res       Date:  1972       Impact factor: 6.242

10.  Reactions of 1,3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in aqueous solution.

Authors:  R J Weinkam; H S Lin
Journal:  J Med Chem       Date:  1979-10       Impact factor: 7.446

View more
  4 in total

1.  Efficacy of interstitial continuous vincristine infusion in a bioluminescent rodent intracranial tumor model.

Authors:  Guifa Xi; Barbara Mania-Farnell; Veena Rajaram; Chandra S Mayanil; Marcelo B Soares; Tadanori Tomita; Stewart Goldman
Journal:  J Neurooncol       Date:  2011-08-14       Impact factor: 4.130

2.  In vitro characterization of the myelotoxicity of cyclopentenyl cytosine.

Authors:  D A Volpe; D L Du; C K Grieshaber; M J Murphy
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Test for chemotherapeutic sensitivity of cerebral gliomas: use of colorimetric MTT assay.

Authors:  J P Jordan; C M Hand; R S Markowitz; P Black
Journal:  J Neurooncol       Date:  1992-09       Impact factor: 4.130

4.  Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model.

Authors:  Grace Y Kim; Betty M Tyler; Malinda M Tupper; Jeffrey M Karp; Robert S Langer; Henry Brem; Michael J Cima
Journal:  J Control Release       Date:  2007-08-15       Impact factor: 9.776

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.